Improving the efficacy of combined modality anticancer therapy using HPMA copolymer-based nanomedicine formulations
- PMID: 19951732
- DOI: 10.1016/j.addr.2009.11.028
Improving the efficacy of combined modality anticancer therapy using HPMA copolymer-based nanomedicine formulations
Abstract
Copolymers based on N-(2-hydroxypropyl)methacrylamide (HPMA) are prototypic and well-characterized polymeric drug carriers that have been broadly implemented in the delivery of anticancer agents. HPMA copolymers circulate for prolonged periods of time, and by means of the Enhanced Permeability and Retention (EPR) effect, they localize to tumors both effectively and selectively. Because of their beneficial biodistribution, and because of the fact that they are able to improve the balance between the efficacy and the toxicity of chemotherapy, it is reasonable to assume that HPMA copolymers combine well with other treatment modalities. In the present review, efforts in this regard are summarized, and HPMA copolymers are shown to be able to beneficially interact with surgery, with radiotherapy, with hyperthermia, with photodynamic therapy, with chemotherapy and with each other. Together, the insights provided and the evidence obtained strongly suggest that HPMA copolymer-based nanomedicine formulations hold significant potential for improving the efficacy of combined modality anticancer therapy.
Copyright 2009 Elsevier B.V. All rights reserved.
Similar articles
-
HPMA-based polymer therapeutics improve the efficacy of surgery, of radiotherapy and of chemotherapy combinations.Nanomedicine (Lond). 2010 Dec;5(10):1501-23. doi: 10.2217/nnm.10.130. Nanomedicine (Lond). 2010. PMID: 21143030
-
Macromolecular nanotheranostics for multimodal anticancer therapy.Nanoscale. 2011 Oct 5;3(10):4022-34. doi: 10.1039/c1nr10733j. Epub 2011 Sep 8. Nanoscale. 2011. PMID: 21901211
-
Effect of radiotherapy and hyperthermia on the tumor accumulation of HPMA copolymer-based drug delivery systems.J Control Release. 2007 Feb 26;117(3):333-41. doi: 10.1016/j.jconrel.2006.10.032. Epub 2006 Nov 25. J Control Release. 2007. PMID: 17215057
-
Beyond oncology--application of HPMA copolymers in non-cancerous diseases.Adv Drug Deliv Rev. 2010 Feb 17;62(2):258-71. doi: 10.1016/j.addr.2009.10.006. Epub 2009 Nov 10. Adv Drug Deliv Rev. 2010. PMID: 19909776 Free PMC article. Review.
-
Do HPMA copolymer conjugates have a future as clinically useful nanomedicines? A critical overview of current status and future opportunities.Adv Drug Deliv Rev. 2010 Feb 17;62(2):272-82. doi: 10.1016/j.addr.2009.12.005. Epub 2009 Dec 11. Adv Drug Deliv Rev. 2010. PMID: 20005271 Review.
Cited by
-
Backbone degradable multiblock N-(2-hydroxypropyl)methacrylamide copolymer conjugates via reversible addition-fragmentation chain transfer polymerization and thiol-ene coupling reaction.Biomacromolecules. 2011 Jan 10;12(1):247-52. doi: 10.1021/bm101254e. Epub 2010 Dec 15. Biomacromolecules. 2011. PMID: 21158387 Free PMC article.
-
Novel Drug Delivery Systems Tailored for Improved Administration of Glucocorticoids.Int J Mol Sci. 2017 Aug 24;18(9):1836. doi: 10.3390/ijms18091836. Int J Mol Sci. 2017. PMID: 28837059 Free PMC article. Review.
-
Objective: tumor. Strategies of drug targeting at the tumor mass level.Clin Transl Oncol. 2014 Jan;16(1):1-10. doi: 10.1007/s12094-013-1075-4. Epub 2013 Jul 12. Clin Transl Oncol. 2014. PMID: 23846244 Review.
-
Clinical developments of antitumor polymer therapeutics.RSC Adv. 2019 Aug 8;9(43):24699-24721. doi: 10.1039/c9ra04358f. eCollection 2019 Aug 8. RSC Adv. 2019. PMID: 35528643 Free PMC article. Review.
-
Stimuli Responsive Polymeric Systems for Cancer Therapy.Pharmaceutics. 2018 Aug 22;10(3):136. doi: 10.3390/pharmaceutics10030136. Pharmaceutics. 2018. PMID: 30131473 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
